NHPC This is like a sexier version of BIEI before it ran. Same pps following a round of dilution. Both have promising drugs in fda pipeline, both trying to sell pain products to support those drugs. The difference is here the SS is lower, the pain products are much better with much much bigger marketing and attempts to distribute. BIEI's pain product launch was one website and one retail location, here we have multiple international distribution plans and a (national?) infomercial for petpainaway. Also here we have orphan drug status which makes phase 2 much cheaper and more likely to happen. Nyloxin was also recently featured on an nbc news story that went national.

BIEI ran from .005 to .02 with a similar ss and float and currently trades at .014

In the recent interview the CEO mentioned the current small note is almost done and no new convertibles until June, at which point he hopes they will have the cash to pay them off. He also mentioned annual sales for 2016 were a little less than 300k, which would be a significant bump up from ytd sales of 139k from the third quarter. Already much higher sales than BIEI.